Compared to patients in the non‐SGLT2 inhibitor group, those in the SGLT2 inhibitor group had a significantly lower incidence of ischaemic strokes/TIA (7.67% vs. 7.01%), corresponding with a 10% lower risk (HR 0.90 [95% CI 0.88‐0.93]; log‐rank P value <0.0001 [Table 3]). Here, SLC5A2 is linked to ischemic stroke.